secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115296
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents reports Q3 product revenue $8.6M (+11% YoY); net loss narrows to $2.3M
--------------------------------------------------------------------------------

- Product revenue $8.6M (+11% YoY); total revenue $9.4M; net loss $2.3M ($0.04/sh) vs $9.2M loss in Q3 2023.
- Product gross margins fell to 61% from 72% due to production slowdown and manufacturing issue now resolved.
- Adjusted EBITDA loss improved to $3.6M from $5.6M in Q3 2023; cash $12.2M at quarter-end vs $14.9M Q2 2024.
- DrugSorb-ATR De Novo application submitted to FDA Sep 27, accepted for review Oct 22; eligible for priority review.
- Received MDSAP certification Nov 1; submitted MDL application to Health Canada Nov 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924115296/0001104659-24-115296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924115296/tm2427790d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer